-
21.发明公开
公开(公告)号：EP3172237A2
公开(公告)日：2017-05-31
申请号：EP15753519.6
申请日：2015-07-21
发明人： BROGDON, Jennifer , CHOI, Eugene , EBERSBACH, Hilmar , GLASS, David , HUET, Heather , JUNE, Carl H. , MANNICK, Joan , MILONE, Michael C. , MURPHY, Leon , PLESA, Gabriela , RICHARDSON, Celeste , RUELLA, Marco , SINGH, Reshma , WANG, Yongqiang , WU, Qilong
CPC分类号： C07K14/705 , A61K35/12 , A61K38/177 , C07K16/2878 , C07K2317/24 , C07K2317/565 , C07K2317/622 , C07K2317/92 , C07K2319/00 , C07K2319/30
摘要： The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
摘要翻译： 本发明提供了用于治疗与BCMA表达相关的疾病的组合物和方法。 本发明还涉及对编码BCMA载体的BCMA载体特异性的嵌合抗原受体（CAR）和包含BCMA CAR的重组T细胞。 本发明还包括施用表达包含BCMA结合结构域的CAR的遗传修饰的T细胞的方法。
-
公开(公告)号：EP4402163A1
公开(公告)日：2024-07-24
申请号：EP22870995.2
申请日：2022-09-16
申请人： The Trustees of The University of Pennsylvania , The Board of Trustees of the Leland Stanford Junior University
发明人： SIURALA, Mikko , JUNE, Carl H. , GARCIA, Kenan Christopher , CASTELLI CORTÉS, Maria Sofia , YOUNG, Regina M.
IPC分类号： C07K14/715 , A61K35/17 , A61P35/00 , C07K14/71
CPC分类号： A61P35/00 , A61K38/00 , C12N15/625 , C07K16/30 , C07K2317/62220130101 , C07K2319/0320130101 , C12N2740/1304320130101 , C12N2740/1604320130101 , C12N5/0636 , C12N2501/5120130101 , C12N2501/51520130101 , C12N2501/230220130101 , C12N2510/0020130101 , C07K14/7155 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K2319/0220130101 , C07K2319/3320130101 , A61K2239/1320230501 , A61K39/464468 , A61K39/4631 , A61K39/4611 , A61K48/005 , A61K2239/2220230501
-
23.发明公开
公开(公告)号：EP4305054A1
公开(公告)日：2024-01-17
申请号：EP22767860.4
申请日：2022-03-09
发明人： SIURALA, Mikko , JUNE, Carl H. , POSEY, Avery , RIBAS, Antoni , KALBASI, Anusha
IPC分类号： C07K14/55 , C12N5/0783 , C07K14/705 , C12N15/861
-
公开(公告)号：EP4275699A2
公开(公告)日：2023-11-15
申请号：EP23193203.9
申请日：2013-02-22
发明人： JUNE, Carl H. , SCHOLLER, John , POSEY, Avery D.
IPC分类号： A61K39/00
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
-
公开(公告)号：EP4036109A3
公开(公告)日：2022-10-12
申请号：EP21209515.2
申请日：2015-12-28
发明人： BEDOYA, Felipe , GHASSEMI, Saba , JUNE, Carl H. , LEVINE, Bruce L. , MELENHORST, Jan J. , MILONE, Michael C. , POWELL, Daniel J. Jr. , ZHENG, Zoe
IPC分类号： C07K14/725 , C12N5/00 , C12N5/0783 , A61K39/00
摘要： The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), and compositions and reaction mixtures comprising the same.
-
26.发明公开
公开(公告)号：EP4056588A1
公开(公告)日：2022-09-14
申请号：EP22162298.8
申请日：2016-04-08
发明人： BITTER, Hans , BORDEAUX, Jennifer Mary , BRANNETTI, Barbara , BROGDON, Jennifer , DAKAPPAGARI, Naveen Kumar , GILL, Saar , HIGHFILL, Steven , HUANG, Lu , JUNE, Carl H. , KIM, Ju Young , LEI, Ming , LI, Na , LOEW, Andreas , ORLANDO, Elena , RUELLA, Marco , TRAN, Thai , ZHANG, Jimin , ZHOU, Li
IPC分类号： C07K14/725 , C07K16/28 , C12N5/0783 , A61K39/00
摘要： The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
-
公开(公告)号：EP4026909A1
公开(公告)日：2022-07-13
申请号：EP22152211.3
申请日：2014-12-19
发明人： BEATTY, Gregory , ENGELS, Boris , IDAMAKANTI, Neeraja , JUNE, Carl H. , LOEW, Andreas , SONG, Huijuan , WU, Qilong
摘要： Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
-
公开(公告)号：EP3660029A1
公开(公告)日：2020-06-03
申请号：EP19199404.5
申请日：2011-12-09
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
-
公开(公告)号：EP2970482B1
公开(公告)日：2019-03-06
申请号：EP14722469.5
申请日：2014-03-15
IPC分类号： C07K16/28 , A61K35/14 , C07K14/725 , C07K14/705 , C07K16/30 , C12N5/0783 , A61P35/00
-
公开(公告)号：EP3214091B1
公开(公告)日：2018-10-03
申请号：EP17153799.6
申请日：2011-12-09
CPC分类号： C12N5/0636 , A61K35/17 , A61K38/177 , A61K38/1774 , A61K39/0011 , A61K39/39558 , A61K45/06 , A61K48/005 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/5256 , A61K2039/585 , C07K14/075 , C07K14/525 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K14/70596 , C07K16/2803 , C07K16/2896 , C07K16/30 , C07K16/3061 , C07K2317/53 , C07K2317/622 , C07K2317/76 , C07K2317/80 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/30 , C07K2319/33 , C07K2319/74 , C12N7/00 , C12N15/85 , C12N15/861 , C12N2501/51 , C12N2501/515 , C12N2510/00 , C12N2740/15034 , C12N2740/15043 , C12N2740/15071 , A61K2300/00
摘要： The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
-
-
-
-
-
-
-
-
-
搜索结果
58 条记录 (耗时 0.039 秒)
